CHICAGO (EGMN) – Long-acting methylphenidate failed to make a dent in cancer-related fatigue in a randomized placebo-controlled phase III trial conducted by the North Central Cancer Treatment Group.
CHICAGO (EGMN) – Long-acting methylphenidate failed to make a dent in cancer-related fatigue in a randomized placebo-controlled phase III trial conducted by the North Central Cancer Treatment Group.
